AVENUE THERAPEUTICS, INC. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Avenue Therapeutics performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

---

1. What does this company do and how did they perform this year?

Avenue Therapeutics develops treatments for acute, severe, and chronic pain. A major highlight this year was selling their subsidiary, Baergic Bio, to Axsome Therapeutics for $10 million in November 2025. This sale allows Avenue to focus its resources on its core project: AJ201, a treatment for spinal and bulbar muscular atrophy (SBMA).

2. Financial performance

Avenue is in the development phase and currently generates no significant product revenue. As of March 2026, the company had about 3.3 million shares outstanding. Operating expenses reached $12.4 million, driven primarily by research and administrative costs. To fund these operations, the company raised $8.5 million in 2025 through public offerings and the exercise of warrants.

3. Major wins and challenges

• The Big Win: The sale of the Baergic subsidiary provided essential cash without the immediate need to issue more shares, helping to lower the company’s spending rate and sharpen their focus on AJ201.
• The Challenge: The company has relied on complex financing structures, including lowering the price of existing warrants to encourage investors to exercise them. While this brings in cash, it results in the issuance of shares at prices below market value, which can put downward pressure on the stock price.

4. Financial health

Avenue reported a loss of $11.8 million for 2025 and held $2.1 million in cash at year-end. Management anticipates these funds will support operations into the second quarter of 2026.

5. Key risks to consider

• Dilution: Because the company consistently sells new shares to fund operations, your ownership percentage may be reduced over time.
• Cash Runway: With a monthly spending rate of approximately $1 million, the company must secure additional funding within the next 3–6 months to continue operations.
• Accounting Volatility: The balance sheet includes "warrant liabilities" that fluctuate in value each quarter. If the stock price rises, these liabilities can create an accounting "loss" that may not reflect the company's actual operational performance.

6. Competitive positioning

Avenue operates in a high-stakes, "binary" environment. Their success hinges entirely on the clinical trial results of AJ201. If the drug fails to meet its endpoints, the company lacks other revenue-generating products to fall back on.

7. Leadership and strategy

An interim CFO is currently managing the company’s finances. The primary strategic focus is balancing a tight cash budget while navigating the data security and regulatory requirements necessary for FDA compliance.

8. Future outlook

Avenue is now fully committed to the development of AJ201. Management is actively pursuing partnerships or licensing deals, as the high costs of clinical trials make it difficult for the company to bring the drug to market independently.

9. Regulatory environment

The company’s path to market relies on specific FDA designations, such as "Fast Track" or "Orphan Drug" status. Changes in FDA policy regarding these designations could significantly impact the timeline and cost of bringing their treatment to patients.

---

Investor Takeaway: Avenue Therapeutics is a high-risk, development-stage company. Because they are currently burning through cash and have no product revenue, your investment decision should weigh their potential breakthrough with AJ201 against the high likelihood of further share dilution and the urgent need for additional capital in the coming months.